Astellas Pharma Inc

Astellas Pharma, founded in Osaka in 1923 and later headquartered in Tokyo, has a robust oncology product pipeline. Astellas Pharma Inc. is a pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of medications. Immunosuppressants, as well as therapies for prostate cancer, acute myeloid leukemia, and overactive bladder, are among the company's primary licensed drugs. Cell therapy for vision treatment, products for allergies and autoimmune illnesses, genetic regulation to advance gene therapy, and mitochondrial replacement therapy are its current top research priority areas.

The company's product portfolio includes marketed products for the treatment of urological disorders, cancer, nephrology, infectious diseases, metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline includes therapeutic candidates for the treatment of urothelial cancer, gastric cancer, gastroesophageal junction cancer, anemia associated with chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis in non-dialysis patients, and acute myeloid leukemia (AML). Through a network of subsidiaries and affiliates, it operates in the Americas, Australia, Europe, Asia, and Oceania. The headquarters of Astellas are in Tokyo, Japan.

Founded: 2005
Headquarters: Tokyo, Japan
Official website: https://www.astellas.com/en/